Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform
MT Newswires Live
Yesterday
Ginkgo Bioworks (DNA) said Tuesday it is partnering with Deep Origin on a 4.5-year project funded by advanced Research Projects Agency for Health, or ARPA-H, to develop a computational platform for predicting drug safety.
Under the collaboration, Ginkgo Bioworks said it will use its Datapoints platform to produce high-throughput data sets for training AI models, including small-molecule and genetic perturbation data across multiple cell and tissue types.
Readouts will include cell type-specific toxicity endpoints, transcriptomics and cell-painting, the company said.
Price: 9.52, Change: +0.12, Percent Change: +1.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.